Corvus Pharma’s $18 Million Bet on Boxer Capital Shows Confidence in This Next Stage of Biotech

On May 15, 2026, Boxer Capital Management disclosed a new position in the Corvus Pharmaceuticals (NASDAQ:CRVS)acquired 1,100,000 shares in the first quarter at an estimated value of $17.55 million based on quarterly prices.

What’s going on

According to a May 15, 2026, SEC filing, Boxer Capital Management disclosed a new position Corvus Pharmaceuticals (NASDAQ:CRVS) by buying 1,100,000 shares in the first quarter. The estimated transaction value is $17.55 million, calculated using the average closing price for that period. The fund reported a quarter-end position value of $16.09 million for Corvus Pharmaceuticals, reflecting both stock accumulation and price change.

Another thing you need to know

• This was Boxer Capital Management’s new position, representing 2.11% of March 31, 2026, reported AUM.

• The top five options after installation:

  • NASDAQ:TNGX: $227.53 million (29.9% of AUM)

  • NASDAQ:KOD: $51.88 million (6.8% of AUM)

  • NASDAQ:RVMD: $48.62 million (6.4% of AUM)

  • NASDAQ:KYMR: $27.41 million (3.6% of AUM)

  • NASDAQ:CELC: $25.68 million (3.4% of AUM)

• As of May 14, 2026, Corvus Pharmaceuticals shares are valued at $13.66, up 250% over the past year, outperforming the S&P 500’s nearly 25% gain.

Company overview

Company summary

• Corvus Pharmaceuticals is developing immuno-oncology therapies, with leads including Mupadolimab (CPI-006) for non-small cell lung cancer and head and neck cancer, CPI-818 for malignant T-cell lymphomas, and Ciforadenant (CPI-444) for renal cell cancer.

• The company uses a clinical-stage biopharmaceutical model, generating value through the development and potential commercialization of monoclonal antibodies and small molecule drugs targeting cancer and immune-related diseases.

• Corvus Pharmaceuticals is proactively working with partners to advance its pipeline and address unmet needs in oncology and immune-related conditions.

Corvus Pharmaceuticals is a clinical-stage biotechnology company focused on developing new immunotherapies for the treatment of cancer. Using a pipeline of monoclonal antibodies and small molecule antagonists, the company aims to address unmet needs in oncology through strategic research and clinical development. Its competitive edge lies in its approach to immune replacement and strategic partnerships to enhance its portfolio.

What this transaction means for investors

Boxer Capital’s willingness to build a large stake in Corvus during a huge run for the company’s stock certainly seems like a strong vote of confidence. Corvus has shifted the focus of investors to atopic dermatitis, where recent Phase 1 data showed strong responses without significant relapses after stopping treatment. In one cohort, 75% of patients achieved EASI 75 responses, and the company also highlighted biomarker data suggesting the possibility of “drug-free remission.” The company has already launched a Phase 2 trial that is expected to enroll about 200 patients.

Financially, Corvus ended the quarter with $236.7 million in cash and marketable securities after raising about $189 million earlier this year, which management said should fund operations through the second quarter of 2028. Meanwhile, the company posted a quarterly loss of $13.7 million as R&D spending increased and trials increased.

For long-term investors, the key question going forward is whether soquelitinib’s immune-resetting narrative can hold up in larger studies. If it does, Corvus could be more than just a small oncology biotech.

Should you buy stock in Corvus Pharmaceuticals right now?

Before buying stock in Corvus Pharmaceuticals, consider the following:

I The Motley Fool Stock Advisor a team of analysts has just identified what they believe to be 10 best stocks for investors to buy now… and Corvus Pharmaceuticals was not one of them. The 10 stocks that made the cut could produce huge gains in the coming years.

Think about when Netflix made this list on December 17, 2004… if you invested $1,000 during our recommendation, you will have $469,293!* Whenever Nvidia made this list on April 15, 2005… if you invested $1,000 during our recommendation, you will have $1,381,332!*

Now, it’s worth noting Stock Advisor’s the average total return is 993% – outperformed the market by 207% for the S&P 500. Don’t miss the latest top 10 list, available via Stock Advisorand join an investment community built by individual investors for individual investors.

See 10 stocks »

*Stock Advisor returns as of May 17, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Kymera Therapeutics. The Motley Fool has a policy of disclosure.

The post Boxer Capital’s $18 Million Bet Signals Corvus Pharma Bet Signals on This Next Stage of Biotech was originally published by The Motley Fool.